Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms

References

• Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10(2):a034876.
   PubMed Web of Science ®Google Scholar
• Chang -C-C, Ohgami RS, eds. Precision molecular pathology of myeloid neoplasms. Springer International Publishing; Berlin 2018
   Google Scholar
• Löfvenberg E, Nilsson T, Wahlin A, et al. Hydroxyurea treatment of myeloproliferative disorders: macro-megaloblastic blood and bone marrow changes. Acta Med Scand. 1987;222(2): 169–4. https://doi.org/10.1111/j.0954-6820.1987.tb10655.x.
   Google Scholar
• Löfvenberg E, Wahlin A, Roos G, et al. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol. 1990;44(1):33–38.
   PubMed Web of Science ®Google Scholar
• Kreft A, Nolde C, Büsche G, et al. Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan. Eur J Haematol. 2000;64(1):32–41.
   PubMed Web of Science ®Google Scholar
• Buhr T, Büsche G, Choritz H, et al. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol. 2003;119(1):152–158.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology. 2003;43(5): 470–479.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Gräff A, et al. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. Histol Histopathol. 2004;19:239–250.
   PubMed Web of Science ®Google Scholar
• Kreft A, Büche G, Ghalibafian M, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113(2):137–143.
   PubMed Web of Science ®Google Scholar
• Shirane S, Araki M, Morishita S, et al. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol. 2015;101(2):148–153.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Ollig S, et al. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol. 2005;20:1071–1076.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A. Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost. 2006;32(4):352–361.
   PubMed Web of Science ®Google Scholar
• Chott A, Gisslinger H, Thiele J, et al. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol. 1990;74(1):10–16.
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Aragona F, et al. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy. Pathol Res Pract. 1993;189(1):52–57.
   PubMed Web of Science ®Google Scholar
• Dalla KP, Zeigler ZR, Shadduck RK. Alpha-interferon in myelofibrosis: a case report. Br J Haematol. 1994;86(3):654–656.
   PubMed Web of Science ®Google Scholar
• Domingues MA, Haepers AT, Massaut IH, et al. Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon. Haematologica. 1998;83:1124–1125.
   PubMed Web of Science ®Google Scholar
• Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern cooperative oncology group. Cancer. 2003;98(1):100–109.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Møller MB, De Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology. 2009;14(331–4):331–334.
   Google Scholar
• Silver RT, Vandris K. Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukaemia. 2009;23(7):1366–1369.
   PubMed Web of Science ®Google Scholar
• Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011;117(24):6669–6672.
   PubMed Web of Science ®Google Scholar
• Silver RT, Lascu E, Feldman EJ, et al. Recombinant interferon alpha (rIFN) may retard progression of early myelofibrosis by reducing splenomegaly and by decreasing marrow fibrosis. Blood. 2013;122(21):4053.
   Google Scholar
• Pizzi M, Rt S, Barel A, et al. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015;28(10): 1315–1323.
   PubMed Web of Science ®Google Scholar
• Utke Rank C, Weis Bjerrum O, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57(2):348–354.
   PubMed Web of Science ®Google Scholar
• Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6(1): 30.
   PubMedGoogle Scholar
• Mikkelsen SU, Kjaer L, Bjorn ME, et al. Safety and efficacy of combination therapy of interferon-alpha2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med. 2018;7(8):3571–3581.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41(1):5–19.
   PubMed Web of Science ®Google Scholar
• Sørensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020;105(9): 2262–2272.
   PubMed Web of Science ®Google Scholar
• Solberg LA, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol. 1997;99(1):174–180.
   PubMed Web of Science ®Google Scholar
• Yoon SY, Li CY, Mesa RA, et al. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106(3):682–688.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Fuchs N, et al. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica. 2003;88:1130–1138.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121(10):1720–1728.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1): 33–45.
   PubMed Web of Science ®Google Scholar
• Hultdin M, Sundström G, Wahlin A, et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007;24(1):63–70.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991–2999.
   PubMed Web of Science ®Google Scholar
• Mela Osorio MJ, Ferrari L, Goette NP, et al. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol. 2016;96(4):435–442.
   PubMed Web of Science ®Google Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol. 1998;61(2):71–76.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019;94(1): 5–9.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol. 2013;31(15_suppl):7030.
   Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of ruxolitinib therapy on megakaryocyte morphology and inflammatory bone marrow reaction in patients with myelofibrosis. Blood. 2013;122(21):4056.
   Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib therapy effectively modulates CD34+ hematopoietic progenitors and bone marrow angiogenesis in patients with myelofibrosis. Blood. 2014;124(21):4578.
   Web of Science ®Google Scholar
• Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98(12):1872–1876.
   PubMed Web of Science ®Google Scholar
• Molica M, Serrao A, Saracino R, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol. 2014;93(11):1951–1952.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Gianelli U, Rapezzi D, et al. Imatinib and ruxolitinib association: first experience in two patients. Haematologica. 2014;99(6):e76–7.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Cattaneo D, Boiocchi L, et al. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib. Ann Hematol. 2015;94(10):1749–1751.
   PubMed Web of Science ®Google Scholar
• Caocci G, Maccioni A, Murgia F, et al. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis. Leuk Lymphoma. 2016;57(5):1215–1218.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [published correction appears in Leukaemia 31(3), 775 (2017)]. Leukaemia. 2017;30(8): 1701–1707.
   Web of Science ®Google Scholar
• Kvasnicka HMD, Thiele J, Bueso-Ramos CE, et al. Effects of long-term ruxolitinib (RUX) on bone marrow (BM) morphology in patients with myelofibrosis (MF) enrolled in the COMFORT-I study. Blood. 2016;128(22):1949.
   Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018;11(1): 42.
   PubMedGoogle Scholar
• Zacharaki D, Ghazanfari R, Li H, et al. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals. Eur J Haematol. 2018;101(1):57–67.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib (RUX) induced meaningful and directional changes in the bone marrow microenvironment of patients with myelofibrosis enrolled in the COMFORT-I study. Blood. 2019;134(Supplement_1):2948.
   Google Scholar
• Harrison CN, Patriarca A, Mascarenhas J, et al. Preliminary report of MANIFEST, a phase 2 study of CPI-0610, a Bromodomain and Extraterminal Domain inhibitor (BETi), in combination with ruxolitinib, in JAK inhibitor (JAKi) treatment naïve myelofibrosis patients. Blood. 2019;134(Supplement_1):4164.
   Google Scholar
• Mascarenhas J, Kremyanskaya M, Hoffman R, et al. MANIFEST, a phase 2 study of CPI-0610, a Bromodomain and Extraterminal Domain inhibitor (BETi), as monotherapy or “add-on” to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis. Blood. 2019;134:670.
   Web of Science ®Google Scholar
• Harrison CN, Garcia JS, Mesa RA, et al. Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis. Blood. 2019;134(Supplement_1):671.
   Google Scholar
• Greenfield G, McPherson S, Mills K, et al. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018;16(1):360.
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Harris NL, et al. eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Revised 4th Edition. Lyon: IARC; 2017.
   Google Scholar